natgillin/translations-raw huggingface dataset:
However the risk of tardive dyskinesia increases with long-term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, a dose reduction or discontinuation should be considered. 
Međutim, rizik od tardivne diskinezije povećava se s dugotrajnom izloženošću te u slučaju pojave znakova ili simptoma tardivne diskinezije u bolesnika na olanzapinu treba razmotriti snižavanje doze ili prekid liječenja.
Mean infant exposure (mg/kg) at steady state was estimated to be 1.8 % of the maternal olanzapine dose (mg/kg). 
Srednja vrijednost izloženosti novorođenčeta (mg/kg) u stanju dinamičke ravnoteže procijenjena je na 1,8% majčine doze olanzapina (mg/kg).
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels 16 
Vrlo često: smanjenje ukupnog bilirubina, povećan GGT, povišene razine prolaktina u plazmi16.
• If you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water tablets) 
• ako znate da možda imate nedovoljno soli u organizmu kao posljedicu dugotrajnog teškog proljeva i povraćanja ili zbog uzimanja diuretika (tableta za izlučivanje vode iz organizma)
Olanzapine Glenmark 2.5 mg tablets Olanzapine Glenmark 5 mg tablets Olanzapine Glenmark 7.5 mg tablets Olanzapine Glenmark 10 mg tablets Olanzapine Glenmark 15 mg tablets Olanzapine Glenmark 20 mg tablets 
Olanzapin Glenmark 2,5 mg tablete Olanzapin Glenmark 5 mg tablete Olanzapin Glenmark 7,5 mg tablete Olanzapin Glenmark 10 mg tablete Olanzapin Glenmark 15 mg tablete Olanzapin Glenmark 20 mg tablete olanzapin
Ventricular tachycardia/fibrillation, sudden death (see section 4.4)11 
ventrikularna tahikardija/ fibrilacija, iznenadna smrt (vidjeti dio 4.4)11
It is important that you carry on taking Olanzapine Glenmark for as long as your doctor tells you. 
Važno je da nastavite uzimati lijek Olanzapine Glenmark onoliko dugo koliko Vam je liječnik rekao.
However, the incidence of death was higher in olanzapine-treated than in placebo-treated patients independent of these risk factors. 
Međutim, incidencija smrtnosti bila je veća u bolesnika liječenih olanzapinom nego u bolesnika koji su primali placebo, neovisno o ovim čimbenicima rizika.
Consult your doctor if your symptoms return but do not stop taking Olanzapine Glenmark unless your doctor tells you to. 
Ako Vam se simptomi vrate, posavjetujte se sa svojim liječnikom, ali nemojte prestati uzimati lijek Olanzapine Glenmark dok Vam liječnik to ne kaže.
The following symptoms may occur in newborn babies, of mothers that have used Olanzapine Glenmark in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. 
Sljedeći simptomi mogu se pojaviti u novorođenčadi majki koje su koristile lijek Olanzapine Glenmark u posljednjem tromjesečju (zadnja tri mjeseca trudnoće): drhtanje, ukočenost mišića i/ili slabost, pospanost, uznemirenost, tegobe s disanjem te poteškoće u hranjenju.
Controlled efficacy data in adolescents (ages 13 to 17 years) are limited to short term studies in schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than 200 adolescents. 
Podaci o djelotvornosti iz kontroliranih ispitivanja u adolescenata (u dobi od 13 do 17 godina) su ograničeni na kratkotrajna ispitivanja u shizofreniji (6 tjedana) i maniji povezanima s bipolarnim poremećajem I (3 tjedna), a obuhvatilo je manje od 200 adolescenata.
Olanzapine administered with lithium or valproate resulted in increased levels (≥ 10 %) of tremor, dry mouth, increased appetite, and weight gain. 
Olanzapin primijenjen s litijem ili valproatom rezultirao je povećanim razinama ( 10%) tremora, suhoće usta, povećanjem apetita i povećanjem tjelesne težine.
The plasma protein binding of olanzapine was about 93 % over the concentration range of about 7 to about 1000 ng/ml. 
Vezanje olanzapina na proteine u plazmi bilo je oko 93% u rasponu koncentracija od približno 7 do približno 1000 ng/ml.
In a retrospective observational cohort study, the risk of presumed sudden cardiac death in patients treated with olanzapine was approximately twice the risk in patients not using antipsychotics. 
U retrospektivnom opservacijskom kohortnom ispitivanju rizik od pretpostavljene iznenadne srčane smrti u bolesnika liječenih olanzapinom bio je otprilike dvostruko veći nego u bolesnika koji nisu uzimali antipsihotike.
• Medicines for Parkinson's disease 
• lijekove protiv Parkinsonove bolesti
The mean increase in olanzapine Cmax following fluvoxamine was 54 % in female non smokers and 77 % in male smokers. 
Srednja vrijednost porasta Cmax olanzapina nakon primjene fluvoksamina iznosio je 54% u žena nepušača i 77% u muškaraca pušača.
• In the early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position. 
U ranim fazama liječenja neki bolesnici mogu osjećati omaglicu ili nesvjesticu (uz usporen rad srca), posebno pri uspravljanju iz ležećeg ili sjedećeg položaja tijela.
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported. 
U istim kliničkim ispitivanjima prijavljeni su cerebrovaskularni štetni događaji (CV štetni događaji, primjerice moždani udar, prolazni ishemijski napad), uključujući smrtne slučajeve.
Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination with other centrally acting medicines and alcohol. 
S obzirom na primarne učinke olanzapina na središnji živčani sustav, oprez je potreban kod njegove primjene u kombinaciji s drugim centralno djelujućim lijekovima i alkoholom.
The daily dose of Olanzapine Glenmark is between 5 mg and 20 mg. 
Dnevna doza lijeka Olanzapine Glenmark iznosi između 5 mg i 20 mg.
Olanzapine was used as a flexible dose starting with 2.5 and ranging up to 20 mg/day. 
Olanzapin se primjenjivao u fleksibilnoj dozi koja je započinjala s 2,5 mg dnevno i postupno je povećavana do 20 mg dnevno.
The most frequently (seen in ≥ 1 % of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema. 
Najčešće prijavljene nuspojave (uočene u ≥ 1% bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glikozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
The concomitant administration of activated charcoal was shown to reduce the oral bioavailability of olanzapine by 50 to 60 %. 
Pokazalo se da istodobna primjena aktivnog ugljena smanjuje oralnu bioraspoloživost olanzapina za 50 do 60%.
During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 520 mg/day. 
Tijekom liječenja shizofrenije, epizode manije te prevencije relapsa bipolarnog poremećaja, dnevna doza se može naknadno podesiti na temelju kliničke slike pojedinog bolesnika u rasponu od 5 do 20 mg/dan.
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 < 1/100), rare (≥ 1/10,000 to< 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available). 
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 
Navedene učestalosti definirane su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10).
Standard procedures for management of overdose may be indicated (i.e. gastric lavage, administration of activated charcoal). 
Mogu biti indicirani standardni postupci za liječenje predoziranja (tj. ispiranje želuca, primjena aktivnog ugljena).
Warnings and precautions Talk to your doctor or pharmacist before you take Olanzapine Glenmark 
Obratite se svom liječniku ili ljekarniku prije nego uzmete lijek Olanzapine Glenmark.
Crospovidone Magnesium stearate 
krospovidon magnezijev stearat
During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks). 
Tijekom liječenja olanzapinom u kombinaciji s litijem ili divalproeksom, porast tjelesne težine  7% od početne pojavio se u 17,4% bolesnika tijekom akutnog liječenja (do 6 tjedana).
However, as clinical experience with olanzapine in patients with concomitant illness is limited, caution is advised when prescribing for patients with prostatic hypertrophy, or paralytic ileus and related conditions. 
Međutim, kako je kliničko iskustvo s olanzapinom u bolesnika s konkomitantnom bolešću ograničeno, savjetuje se oprez pri propisivanju lijeka bolesnicima s hipertrofijom prostate ili paralitičkim ileusom i povezanim stanjima.
Cytochromes P450-CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies. 
Citokromi P450-CYP1A2 i P450-CYP2D6 doprinose stvaranju N-dezmetil i 2-hidroksimetil metabolita te u ispitivanjima na životinjama oba pokazuju značajno manje in vivo farmakološko djelovanje od olanzapina.
Do not stop taking your tablets just because you feel better. 
Ako prestanete uzimati lijek Olanzapine Glenmark Nemojte prestati uzimati tablete samo zato jer se osjećate bolje.
Olanzapine should be used cautiously in patients who have a history of seizures or are subject to factors, which may lower the seizure threshold. 
Olanzapin treba oprezno primjenjivati u bolesnika imaju napadaje u anamnezi ili su izloženi čimbenicima koji mogu sniziti prag za napadaje.
Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebocontrolled clinical trials (see section 4.8). 
Neželjene promjene vrijednosti lipida uočene su u bolesnika liječenih olanzapinom u placebom kontroliranim kliničkim ispitivanjima (vidjeti dio 4.8).
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of ≥ 7 % from baseline body weight in 39.9 % of patients. 
Dugotrajno liječenje olanzapinom (do 12 mjeseci) radi prevencije relapsa u bolesnika s bipolarnim poremećajem bilo je povezano s povećanjem tjelesne težine  7% od početne tjelesne težine u 39,9% bolesnika.
Very common symptoms in overdose (> 10 % incidence) include tachycardia, agitation/ aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma. 
Vrlo česti simptomi predoziranja (incidencija > 10%) obuhvaćaju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidalne simptome te smanjenu razinu svijesti u rasponu od sedacije do kome.
8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30% of olanzapine treated patients with normal baseline prolactin value. 
8 U kliničkim ispitivanjima u trajanju do 12 tjedana koncentracije prolaktina u plazmi prelazile su gornju granicu normalnog raspona u približno 30% bolesnika liječenih olanzapinom s normalnom početnom vrijednošću prolaktina.
Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose). 
Reverzibilna neutropenija, trombocitopenija ili anemija razvile su se u malog broja pasa liječenih dozom od 8 ili 10 mg/kg/dan (ukupna izloženost olanzapinu [AUC] je 12 do 15 puta veća nego izloženost u čovjeka kojemu je dana doza od 12 mg).
In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis. 
U ispitivanju je rizik povezan s olanzapinom bio usporediv s rizikom povezanim s atipičnim antipsihoticima uključenima u objedinjenu analizu.
New born infants exposed to antipsychotics (including olanzapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. 
U novorođenčadi izloženoj antipsihoticima (uključujući olanzapin) tijekom trećeg tromjesečja trudnoće postoji rizik od nastanka nuspojava, uključujući ekstrapiramidne simptome i/ili simptome ustezanja koji nakon poroda mogu varirati po težini i trajanju.
DRESS appears initially as flu-like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia). 
najprije nastupa u obliku simptoma nalik gripi praćenih osipom na licu, a zatim se javljaju proširen osip, visoka tjelesna temperatura, povećani limfni čvorovi, povišene vrijednosti jetrenih enzima vidljive u nalazima krvnih pretraga te povišene vrijednosti jedne vrste bijelih krvnih stanica (eozinofilija).
There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. 
Postoje izvješća o agitaciji, hipertoniji, hipotoniji, tremoru, somnolenciji, respiratornom distresu ili poremećaju hranjenja.
Olanzapine Glenmark has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment. 
Pokazalo se da Olanzapine Glenmark sprječava ponavljanje tih simptoma u bolesnika s bipolarnim poremećajem u kojih je epizoda manije reagirala na liječenje olanzapinom.
6.4 Special precautions for storage Store below 30C 
6.4 Posebne mjere pri čuvanju lijeka Čuvati na temperaturi ispod 30°C.
Do not drink any alcohol if you have been given Olanzapine Glenmark as together with alcohol it may make you feel drowsy. 
Nemojte piti alkohol ako uzimate lijek Olanzapine Glenmark jer u kombinaciji s alkoholom može izazvati omamljenost.
31, D - 82194 Gröbenzell, Germany 
Industriestr. 31, D-82194, Gröbenzell, Njemačka
Pharmacotherapeutic group: psycholeptics, diazepines, oxazepines, thiazepines and oxepines, ATC code N05A H03. 
Farmakoterapijska skupina: psiholeptici, diazepini, oksazepini, tiazepini i oksepini, ATK oznaka: N05AH03.
Patients treated with any antipsychotic medicines, including olanzapine, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control. 
U bolesnika liječenih bilo kojim antipsihotikom, uključujući lijek Olanzapine Glenmark, treba pratiti pojavu znakova i simptoma hiperglikemije (kao što su polidipsija, poliurija, polifagija i slabost), a bolesnike s dijabetesom melitusom ili čimbenicima rizika za razvoj dijabetesa melitusa treba redovito pratiti zbog mogućeg pogoršanja glikemije.
Do not take Olanzapine Glenmark - if you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine (listed in section 6). 
• Ako ste alergični (preosjetljivi) na olanzapin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
- The use of Olanzapine Glenmark in elderly patients with dementia is not recommended as it may have serious side effects. 
• Primjena lijeka Olanzapine Glenmark u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
70 tablets 
70 tableta
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson's disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo. 
U kliničkim ispitivanjima u bolesnika s psihozom uzrokovanom lijekovima (agonisti dopamina) povezanom s Parkinsonovom bolešću vrlo često je zabilježeno pogoršanje simptoma parkinsonizma i halucinacija i češće nego s placebom.
Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (< 2 % of overdose cases) and cardiopulmonary arrest. 
Druge medicinski značajne posljedice predoziranja obuhvaćaju delirij, konvulzije, komu, mogući neuroleptički maligni sindrom, respiratornu depresiju, aspiraciju, hipertenziju ili hipotenziju, srčane aritmije (< 2% slučajeva predoziranja) i kardiopulmonalni arest.
You should swallow the Olanzapine Glenmark tablets whole, with water. 
Olanzapine Glenmark tablete morate progutati cijele s vodom.
The clinical consequences are likely to be limited, but clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.2). 
Kliničke posljedice su vjerojatno ograničene, ali se preporučuje kliničko praćenje te se može razmotriti povećanje doze olanzapina, ako je to potrebno (vidjeti dio 4.2).
In cytopenic dogs, there were no adverse effects on progenitor and proliferating cells in the bone marrow. 
U pasa s citopenijom nije bilo štetnih učinaka za matične i proliferacijske stanice koštane srži.
If this happens after you have been given Olanzapine Glenmark tell your doctor. 
Ako Vam se ovo pojavi nakon uzimanja lijeka Olanzapine Glenmark, obratite se svom liječniku.
If you suddenly stop taking Olanzapine Glenmark, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. 
Ako naglo prestanete s uzimanjem lijeka Olanzapine Glenmark mogu se pojaviti simptomi poput znojenja, nesanice, nevoljnog drhtanja, tjeskobe ili mučnine i povraćanja.
- Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. 
• Vrlo rijetko lijekovi ovog tipa uzrokuju kombinaciju vrućice, ubrzanog disanja, znojenja, ukočenosti mišića te omamljenosti ili pospanosti.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake "Rok valjanosti".
High Gamma Glutamyltransferase High uric acid 10 
visoka gama glutamiltransferaza visoka razina mokraćne kiseline10
10 As assessed by measured values from clinical trials in the Olanzapine Integrated Database. 
10 Procijenjeno na temelju izmjerenih vrijednosti iz kliničkih ispitivanja u integriranoj bazi podataka za olanzapin.
• Serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). 
Vrlo rijetke nuspojave uključuju ozbiljne alergijske reakcije poput reakcije na lijek uz eozinofiliju i sistemske simptome (engl. drug reaction with eosinophilia and systemic symptoms, DRESS).
Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines. 
Potreban je oprez i kontrola u bolesnika s povišenim ALT-om i/ili ASTom, u bolesnika sa znakovima i simptomima oštećenja jetre, u bolesnika s prethodno postojećim stanjima povezanima s ograničenom funkcionalnom rezervom jetre te u bolesnika koji se liječe potencijalno hepatotoksičnim lijekovima.
6 In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo. 
6 U kliničkim ispitivanjima incidencija parkinsonizma i distonije u bolesnika liječenih olanzapinom bila je brojčano veća, ali nije bila statistički značajno različita u odnosu na placebo.
Other medicines and Olanzapine Glenmark 
Drugi lijekovi i Olanzapine Glenmark
Effects on haematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found. 
U svakoj su vrsti pronađeni učinci na hematološke parametre, uključujući smanjenje broja cirkulirajućih leukocita ovisno o dozi u miševa te nespecifično smanjenje broja cirkulirajućih leukocita u štakora.
All olanzapine and placebo-treated patients who experienced a cerebrovascular event had pre-existing risk factors. 
Svi bolesnici liječeni olanzapinom i bolesnici koji su primali placebo, a u kojih se javio cerebrovaskularni događaj, prethodno su imali čimbenike rizika.
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term clinical trials in adolescent patients. 
Sljedeća tablica sažima nuspojave prijavljene s većom učestalošću u adolescentnih bolesnika (u dobi od 13 do 17 godina) u odnosu na odrasle bolesnike ili nuspojave identificirane samo u kratkotrajnim kliničkim ispitivanjima u adolescentnih bolesnika.
In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr). 
U bolesnika s oštećenjem bubrega (klirens kreatinina < 10 ml/min) nije bilo značajne razlike u odnosu na zdrave ispitanike u prosječnom poluvremenu eliminacije (37,7 naspram 32,4 sata) ili klirensu (21,2 naspram 25,0 l/h).
Thus no particular interaction is expected as verified through in vivo studies where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2) or diazepam (CYP3A4 and CYP2C19). 
Stoga se ne očekuje nikakva posebna interakcija, što potvrđuju in vivo ispitivanja u kojima nije nađena inhibicija metabolizma sljedećih djelatnih tvari: tricikličkih antidepresiva (predstavljaju glavninu CYP2D6 puta), varfarina (CYP2C9), teofilina (CYP1A2) ili diazepama (CYP3A4 i 2C19).
12 Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database. 
12 Nuspojava je identificirana iz spontanih prijava nakon stavljanja lijeka u promet, a učestalost je određena na gornjoj granici 95%-tnog intervala pouzdanosti uz pomoć integrirane baze podataka za olanzapin.